Media Centre
Latest press releases
-
AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025
-
Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer
-
Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy
-
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
-
Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle cell lymphoma
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
